Abstract
Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Poulet H, Minke J, Pardo MC et al (2007) Development and registration of recombinant veterinary vaccine. The example of the canarypox vector platform. Vaccine 25(30):5606–5612
Draper SJ, Heeney JL (2010) Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8(1):62–73
Weli SC, Tryland M (2011) Avipoxviruses: infection biology and their use as vaccine vectors. Virol J 8:49
Staib C, Drexler I, Sutter G (2004) Construction and Isolation of Recombinant MVA. In: Isaacs SN (ed) Vaccinia virus and poxvirology methods and protocols, 1st edn. Humana, Totowa, NJ
Calamante G, Conte Grand MD, Carrillo EC (2010) Argentinian Patent AR052743B1
Green MR, Sambrook J (2012) Molecular cloning: a laboratory manual, 4th edition. In: Inglis J, Boyle A, Gann A (eds) Expressing cloned genes for protein production, purification and analysis, chapter 19, vol 3. Cold Spring Harbor Laboratory Press, New York, pp 1602–1630
Boyle DB (1992) Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants. Virus Genes 6:281–290
Taylor J, Meignier B, Tartaglia J et al (1995) Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13:539–549
Amano H, Morikawa S, Shimizu H et al (1999) Identification of the canarypoxvirus thymidine kinase gene and insertion of foreign genes. Virology 256:280–290
Zanetti FA, Conte Grand MD, Mitarotonda RC et al (2014) Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens. Braz J Microbiol 45:231–234
Blasco R, Moss B (1995) Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 158:157–162
Coupar BE, Andrew ME, Both GW, Boyle DB (1986) Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol 16:1479–1487
Rosel J, Earl P, Weir J, Moss B (1986) Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment. J Virol 60:436–449
Tulman ER, Afonso CL, Lu Z et al (2004) The genome of canarypox virus. J Virol 78:353–366
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Garanzini, D., Del Médico-Zajac, M.P., Calamante, G. (2017). Development of Recombinant Canarypox Viruses Expressing Immunogens. In: Ferran, M., Skuse, G. (eds) Recombinant Virus Vaccines. Methods in Molecular Biology, vol 1581. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6869-5_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6869-5_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6867-1
Online ISBN: 978-1-4939-6869-5
eBook Packages: Springer Protocols